First Wave BioPharma, Inc. (FWBI)
| Previous Close | 5.1600 |
| Open | 5.1000 |
| Bid | 4.7600 x 3100 |
| Ask | 4.8300 x 1400 |
| Day's Range | 4.6550 - 5.3000 |
| 52 Week Range | 3.0100 - 348.6000 |
| Volume | |
| Avg. Volume | 526,810 |
| Market Cap | 4.756M |
| Beta (5Y Monthly) | 1.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.1880 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.00 |
- GlobeNewswire
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
Patient dosing expected to begin in mid-February with topline data anticipated by mid-2023BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric micro
- GlobeNewswire
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
Patient screening to initiate; topline data expected by mid-2023BOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will initiate its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase
- GlobeNewswire
First Wave BioPharma to Present at the BIO CEO & Investor Conference
BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as fo
